Last reviewed · How we verify
recombinant FSH or hMG
At a glance
| Generic name | recombinant FSH or hMG |
|---|---|
| Also known as | Gonal F, Merional |
| Sponsor | Yazd Research & Clinical Center for Infertility |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) (PHASE3)
- Does Recombinant FSH (rFSH, i.g. Gonal F®) as Compared to Human Menopausal Gonadotrophin (hMG) Affect Telomere Length of Cumulus Cells During Antral Follicle Growth and Impact Blastocyst Status?
- Trigger Protocol on the Rate of Pregnancy After Intracytoplasmic Sperm Injection
- Effect of GnRH Agonist Treatment Protocols on Ovarian Reserve (NA)
- Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI (PHASE4)
- Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes. (PHASE4)
- Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI (PHASE4)
- Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- recombinant FSH or hMG CI brief — competitive landscape report
- recombinant FSH or hMG updates RSS · CI watch RSS
- Yazd Research & Clinical Center for Infertility portfolio CI